Extended Data Table 2 Vital sign measures in humans after a single ascending dose (A) or multiple ascending doses (B) of placebo and AMG 133

From: A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

  1. Data presented as mean (SD). N, total number of participants within each group.
Back to article page